Award

National Institute of Allergy and Infectious Diseases 2R01AI151167-05A1

Manipulating alpha(v) integrins on B cells to promote lung-resident B cell responses

Recipient

Seattle Children's Hospital, Seattle, WA, United States

Award Amount

$767,781.00

Ceiling

$767,781.00

Awarded

March 27, 2026

Identifier

2R01AI151167-05A1

The award supports research on enhancing lung-resident B cell responses by manipulating alpha(v) integrins to improve immunity against respiratory viruses, aiming to develop better vaccines and therapeutic strategies.

Description

This project aims to investigate how B cell TLR signaling promotes germinal center responses, establish the protective capacity of lung-resident B cells, and evaluate αv antagonists in mice and human B cell cultures to enhance mucosal immune responses. The research addresses mechanisms promoting respiratory immunity and explores therapeutic strategies to enhance tissue-resident immune responses, potentially leading to new vaccine adjuvants.

View original record